A timely comprehensive molecular testing of those cases wild-type for the common thyroid carcinoma <i>BRAF</i> V600E-like and <i>RAS</i>-like driver mutations may uncover actionable gene rearrangements that can be targeted by highly selective inhibitors with great potential benefit for the patients. The gene discussed is BRAF; the disease is thyroid gland carcinoma.